Lords Call For UK Government To Secure A ‘Growth’ Pricing Deal With Pharma
The House of Lords held a debate on the UK’s statutory drug pricing scheme as a way of drawing attention to the need for a voluntary price deal that can revive the international competitiveness of the life science industry.
You may also be interested in...
Much-needed investment could be lost if the “uncompetitive” sales rebate rate is not reduced as part of talks on a new UK drug pricing scheme, some parliamentarians are warning.
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.
The UK government says that payments need to rise if the stability of the statutory and voluntary drug pricing schemes is to be ensured.